Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Hematol Oncol ; 39(3): 336-348, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33583077

ABSTRACT

Transplant-ineligible relapsed/refractory (rr) diffuse large B-cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), an anti-CD79b antibody-drug-conjugate (ADG), with bendamustine- rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on the GO29365 phase IIb trial. Real-life data with Pola are extremely limited. We report the outcomes of 61 Greek patients, who received Pola-(B)R mainly within a compassionate use program. Treatment was given for up to six 21-day cycles. Bendamustine was omitted in three cases due to previous short-lived responses. Fourty-nine rrDLBCL(efficacy cohort-EC) and 58 rr aggressive B-NHL (safety cohort-SC) patients received at least 1 Pola-BR cycle. Twenty-one (43%) patients of the EC responded with 12/49 (25%) CR and 9/49 (18%) PR as best response. Median progression-free survival, overall survival and duration of response were 4.0, 8.5, and 8.5 months respectively, while 55% of patients experienced a grade ≥3 adverse event, mainly hematologic. Treatment discontinuations and death during treatment were mainly due to disease progression. Twenty-two (41%) patients received further treatment; 11/22 are still alive, including one after CAR-T cells, and two after stem cell transplantation. Our data confirm that Pola-BR is a promising treatment for rrDLBCL patients, inducing an adequate response rate with acceptable toxicity. Pola-BR could be used as bridging therapy before further consolidative treatments.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/mortality , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bendamustine Hydrochloride/administration & dosage , Bendamustine Hydrochloride/adverse effects , Disease-Free Survival , Female , Greece/epidemiology , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/adverse effects , Male , Middle Aged , Rituximab/administration & dosage , Rituximab/adverse effects , Survival Rate
2.
Isr Med Assoc J ; 18(9): 524-529, 2016 Sep.
Article in English | MEDLINE | ID: mdl-28471597

ABSTRACT

BACKGROUND: Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by vascular thrombosis (arterial or venous) and/or pregnancy complications associated with the occurrence of autoantibodies, specifically lupus anticoagulant, anticardiolipin antibodies, and/or anti-ß2 glycoprotein-I antibodies confirmed at least twice over a 12 week period according to the 2006 Sydney criteria. Antiphospholipid antibodies are encountered  in the general population with a reported prevalence of 1% to 5%  However, APS is far more infrequent with a prevalence of 40-50/100,000 persons and an incidence of about 5 new patients/100,000 persons. APS can be diagnosed in patients with no apparent clinical or laboratory pathology (primary APS) or it may be related to numerous other conditions, autoimmune diseases (usually systemic lupus erythematosus), malignancies, infections and drugs (secondary APS). Women are at risk for APS since the disease is encountered in both the primary and the secondary state in females more often than in men. In addition, women in their reproductive years can develop APS (either classical or obstetric), and special attention is warranted in pregnant women with a diagnosis of APS. The benefits of hormonal therapy in the form of contraception or hormone replacement treatment should be carefully weighed against the increased risk for vascular complications in women with APS.


Subject(s)
Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Autoantibodies/immunology , Antibodies, Anticardiolipin/immunology , Antiphospholipid Syndrome/epidemiology , Antiphospholipid Syndrome/etiology , Female , Hormone Replacement Therapy/adverse effects , Hormone Replacement Therapy/methods , Humans , Lupus Coagulation Inhibitor/immunology , Male , Pregnancy , Pregnancy Complications/immunology , Prevalence , Thrombosis/immunology
3.
J Immunol Res ; 2015: 478753, 2015.
Article in English | MEDLINE | ID: mdl-25950010

ABSTRACT

TACI is a membrane receptor of BAFF and APRIL, contributing to the differentiation and survival of normal B cells. Although malignant B cells are also subjected on TACI signaling, there is a remarkable intradisease and interindividual variability of TACI expression in B-cell malignancies. The aim of our study was to explore the possible role of TACI signaling in the biology of chronic lymphocytic leukemia (CLL), including its phenotypic and clinical characteristics and prognosis. Ninety-four patients and 19 healthy controls were studied. CLL patients exhibited variable TACI expression, with the majority of cases displaying low to undetectable TACI, along with low to undetectable BAFF and increased APRIL serum levels compared to healthy controls. CLL cells with high TACI expression displayed a better survival capacity in vitro, when cultured with BAFF and/or APRIL. Moreover, TACI expression was positively correlated with the presence of monoclonal gammopathy and inversely with CD11c expression. Therefore, our study provides further evidence for the contribution of BAFF/APRIL signaling to CLL biology, suggesting also that TACI detection might be useful in the selection of patients for novel targeting therapeutic approaches.


Subject(s)
B-Cell Activating Factor/blood , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Transmembrane Activator and CAML Interactor Protein/blood , Tumor Necrosis Factor Ligand Superfamily Member 13/blood , Adult , Aged , Aged, 80 and over , Apoptosis/genetics , Apoptosis/immunology , B-Lymphocytes/cytology , B-Lymphocytes/pathology , CD11c Antigen/biosynthesis , Cell Differentiation/genetics , Cell Differentiation/immunology , Female , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Middle Aged , Paraproteinemias/genetics , RNA, Messenger/biosynthesis , Signal Transduction/genetics , Signal Transduction/immunology , Transmembrane Activator and CAML Interactor Protein/biosynthesis , Transmembrane Activator and CAML Interactor Protein/genetics
4.
Leuk Res ; 32(2): 339-41, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17560647

ABSTRACT

We report a case of a 68-year-old man presented with upper-gastrointestinal bleeding. Endoscopy showed a large ulcerated gastric mass. Histological examination of the gastric biopsies revealed a k monoclonal extramedullary plasmacytoma (EMP). Further staging was negative for multiple myeloma. The patient was managed with bortezomib at a dose of 1.3mg/m2 on days 1, 4, 8 and 11 of a 21-day cycle in combination with dexamethasone 20mg p.o. on days 1, 2, 4, 5, 8, 9 and 11, 12 of each cycle. After 4 cycles of treatment, no endoscopic or histological findings of EMP were found. Thirteen months after diagnosis the patient is in complete remission with no evidence of local relapse or evolution to multiple myeloma. This is the first reported case of EMP successfully managed with the combination of bortezomib and dexamethasone.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Plasmacytoma/drug therapy , Stomach Neoplasms/drug therapy , Boronic Acids/administration & dosage , Bortezomib , Dexamethasone/administration & dosage , Humans , Male , Middle Aged , Plasmacytoma/pathology , Plasmacytoma/physiopathology , Pyrazines/administration & dosage , Stomach Neoplasms/pathology , Stomach Neoplasms/physiopathology
5.
Ann Hematol ; 86(5): 369-76, 2007 May.
Article in English | MEDLINE | ID: mdl-17375302

ABSTRACT

The aim of the study was to evaluate the role of hypochromic erythrocytes (HYPO%) compared to "traditional" and novel markers of iron status and erythropoiesis in recognizing iron-restricted erythropoiesis (IRE) and predicting response to erythropoietin (rHuEPO) in anemic patients with myeloma and lymphoma. Forty-one newly diagnosed patients who received epoetin-beta at a subcutaneous weekly dose of 30,000 IU for 6 weeks were studied. Response to rHuEPO was observed in 27 patients (65.8%). Twelve non-responders received, additionally, 200 mg of IV iron sucrose, weekly, for 4 weeks. Evaluation of markers was performed at baseline and on weeks 1, 2 and 6 for all patients and also on weeks 7-10 for non-responders to rHuEPO. Baseline HYPO%, at a cut-off value of <5%, and an increment in reticulocyte absolute number (RETICS-AB) >or= 50,000/microl and reticulocyte hematocrit (RETICS-Hct) >or= 50%, between baseline and week 2, were independent predictive factors for response to rHuEPO. We found that these markers had superior predictive value for response to rHuEPO than four widely used predictive models. Furthermore, a baseline HYPO% count of above 5% proved superior over serum ferritin < 100 ng/ml and transferrin saturation < 20% in recognizing IRE. In conclusion, baseline HYPO% either alone or in combination with RETICS-AB or RETICS-Hct after 2 weeks of rHuEPO treatment could be reliably used in predicting response to rHuEPO. Additionally, HYPO% has proved a reliable marker for recognizing IRE before rHuEPO treatment and, thus, could be used for identifying patients who will benefit from IV iron supplementation.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Erythrocyte Indices/drug effects , Erythrocytes/chemistry , Erythropoiesis/drug effects , Erythropoietin/therapeutic use , Hematinics/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Anemia, Iron-Deficiency/etiology , Biomarkers , Erythrocytes/classification , Erythropoietin/pharmacology , Female , Hematinics/pharmacology , Hematocrit , Humans , Lymphoma/complications , Lymphoma/drug therapy , Male , Middle Aged , Multiple Myeloma/complications , Multiple Myeloma/drug therapy , Predictive Value of Tests , Recombinant Proteins
6.
Leuk Res ; 31(4): 559-62, 2007 Apr.
Article in English | MEDLINE | ID: mdl-16820206

ABSTRACT

Thrombocytosis is not a frequent event in myelodysplasia (MDS) and is observed mainly in 5q- syndrome and MDS/myeloproliferative (MPD) overlap syndromes. The pathogenetic mechanism of thrombocytosis in 5q- has not been fully elucidated to-date. Bortezomib is a proteasome inhibitor which seems to be effective in MDS. We present here the first case in the literature with MDS/MPD syndrome, sole 5q- anomaly and thrombocytosis in which bortezomib administration normalized platelet count, produced a major erythroid response, and reduced levels of interleukin-6 (IL-6) and TNF-alpha while increased levels of IL-4 in the bone marrow plasma. The study of such cases will reveal the exact role of bortezomib in the management of MDS/MPD.


Subject(s)
Antineoplastic Agents/therapeutic use , Boronic Acids/therapeutic use , Chromosomes, Human, Pair 5/genetics , Myelodysplastic Syndromes/drug therapy , Myeloproliferative Disorders/drug therapy , Pyrazines/therapeutic use , Thrombocytosis/drug therapy , Bortezomib , Female , Humans , Interleukin-4/metabolism , Interleukin-6/metabolism , Middle Aged , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/genetics , Myeloproliferative Disorders/complications , Myeloproliferative Disorders/genetics , Platelet Count , Thrombocytosis/complications , Thrombocytosis/genetics , Tumor Necrosis Factor-alpha/metabolism
7.
Br J Haematol ; 134(6): 620-3, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16889620

ABSTRACT

The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only patients who received bisphosphonates developed ONJ (28/254; 11%). Zoledronic acid produced 9.5-fold greater risk for developing ONJ than pamidronate alone (P = 0.042) and 4.5-fold greater risk than subsequent use of pamidronate + zoledronic acid (P = 0.018). Use of thalidomide and number of bisphosphonate infusions also increased the risk for ONJ by 2.4-fold (P = 0.043), and 4.9-fold respectively (P = 0.012). ONJ developed earlier among patients receiving zoledronic acid. Our data indicates that administration of zoledronic acid for more than 2 years or in combination with thalidomide requires caution in myeloma.


Subject(s)
Jaw Diseases/pathology , Multiple Myeloma/pathology , Osteonecrosis/pathology , Aged , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Drug Administration Schedule , Female , Humans , Incidence , Jaw Diseases/chemically induced , Jaw Diseases/diagnostic imaging , Male , Middle Aged , Multiple Myeloma/diagnostic imaging , Multiple Myeloma/drug therapy , Osteonecrosis/chemically induced , Osteonecrosis/diagnostic imaging , Pamidronate , Risk Factors , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...